<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SUMATRIPTAN SUCCINATE- sumatriptan succinate injection </strong><br>Teva Parenteral Medicines, Inc<br></p></div>
<h1>Sumatriptan Succinate Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">Package Insert</p>
<p>Rx only</p>
<p>For Subcutaneous Use Only. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sumatriptan succinate injection is a selective 5-hydroxytryptamine<span class="Sub">1</span> receptor subtype agonist. Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1), and it has the following structure: </p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24259865-233b-4258-a01b-e895a873f2c4&amp;name=sumatriptan-01.jpg"></div>
<p>The molecular formula is C<span class="Sub">14</span>H<span class="Sub">21</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S•C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">4</span>, representing a molecular weight of 413.5. </p>
<p>Sumatriptan succinate is a white to off-white powder that is readily soluble in water and in saline. </p>
<p>Sumatriptan succinate injection is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 0.5 mL of sumatriptan succinate injection 12 mg/mL solution contains 6 mg of sumatriptan (base) as the succinate salt and 3.5 mg of sodium chloride, USP in water for injection, USP. The pH range of the solution is approximately 4.2 to 5.3. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of the injection is 291 mOsmol. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Sumatriptan has been demonstrated to be a selective agonist for a vascular 5-hydroxytryptamine<span class="Sub">1</span> receptor subtype (probably a member of the 5-HT<span class="Sub">1D</span> family) with no significant affinity (as measured using standard radioligand binding assays) or pharmacological activity at 5-HT<span class="Sub">2</span>, 5-HT<span class="Sub">3</span> receptor subtypes or at alpha<span class="Sub">1</span>-, alpha<span class="Sub">2</span>-, or beta-adrenergic; dopamine<span class="Sub">1</span>; dopamine<span class="Sub">2</span>; muscarinic; or benzodiazepine receptors. </p>
<p>The vascular 5-HT<span class="Sub">1</span> receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, has been shown to be present on cranial arteries in both dog and primate, on the human basilar artery, and in the vasculature of the isolated dura mater of humans. In these tissues, sumatriptan activates this receptor to cause <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, an action in humans correlating with the relief of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> and <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>. In the anesthetized dog, sumatriptan selectively reduces the carotid arterial blood flow with little or no effect on arterial blood pressure or total peripheral resistance. In the cat, sumatriptan selectively constricts the carotid arteriovenous anastomoses while having little effect on blood flow or resistance in cerebral or extracerebral tissues. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CPCO"></a><a name="section-3.2"></a><p></p>
<h2>Corneal Opacities</h2>
<p class="First">Dogs receiving oral sumatriptan developed corneal opacities and defects in the corneal epithelium. Corneal opacities were seen at the lowest dosage tested, 2 mg/kg/day, and were present after 1 month of treatment. Defects in the corneal epithelium were noted in a 60-week study. Earlier examinations for these toxicities were not conducted and no-effect doses were not established; however, the relative exposure at the lowest dose tested was approximately 5 times the human exposure after a 100-mg oral dose or 3 times the human exposure after a 6-mg subcutaneous dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CPMB"></a><a name="section-3.3"></a><p></p>
<h2>Melanin Binding</h2>
<p class="First">In rats with a single subcutaneous dose (0.5 mg/kg) of radiolabeled sumatriptan, the elimination half-life of radioactivity from the eye was 15 days, suggesting that sumatriptan and its metabolites bind to the melanin of the eye. The clinical significance of this binding is unknown. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="CPPharmacokinetics"></a><a name="section-3.4"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Pharmacokinetic parameters following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age, 33 years; mean weight, 77 kg) were systemic clearance: 1,194 ± 149 mL/min (mean ± S.D.), distribution half-life: 15 ± 2 minutes, terminal half-life: 115 ± 19 minutes, and volume of distribution central compartment: 50 ± 8 liters. Of this dose, 22% ± 4% was excreted in the urine as unchanged sumatriptan and 38% ± 7% as the indole acetic acid metabolite. </p>
<p>After a single 6-mg subcutaneous manual injection into the deltoid area of the arm in 18 healthy males (age, 24 ± 6 years; weight, 70 kg), the maximum serum concentration (C<span class="Sub">max</span>) was (mean ± standard deviation) 74 ± 15 ng/mL and the time to peak concentration (T<span class="Sub">max</span>) was 12 minutes after injection (range, 5 to 20 minutes)<span class="Italics">.</span> In this study, the same dose injected subcutaneously in the thigh gave a C<span class="Sub">max</span> of 61 ± 15 ng/mL by manual injection versus 52 ± 15 ng/mL by autoinjector techniques. The T<span class="Sub">max</span> or amount absorbed was not significantly altered by either the site or technique of injection. </p>
<p>The bioavailability of sumatriptan via subcutaneous site injection to 18 healthy male subjects was 97% ± 16% of that obtained following intravenous injection. Protein binding, determined by equilibrium dialysis over the concentration range of 10 to 1,000 ng/mL, is low, approximately 14% to 21%. The effect of sumatriptan on the protein binding of other drugs has not been evaluated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of sumatriptan has not been examined, but little clinical effect would be expected as sumatriptan is largely metabolized to an inactive substance. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the pharmacokinetics of subcutaneously and orally administered sumatriptan has been evaluated. There were no statistically significant differences in the pharmacokinetics of subcutaneously administered sumatriptan in hepatically impaired patients compared to healthy controls. However, the liver plays an important role in the presystemic clearance of orally administered sumatriptan. Accordingly, the bioavailability of sumatriptan following oral administration may be markedly increased in patients with liver disease. In 1 small study of hepatically impaired patients (n = 8) matched for sex, age, and weight with healthy subjects, the hepatically impaired patients had an approximately 70% increase in AUC and C<span class="Sub">max</span> and a T<span class="Sub">max</span> 40 minutes earlier compared to the healthy subjects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.3"></a><p></p>
<h3>Age</h3>
<p class="First">The pharmacokinetics of sumatriptan in the elderly (mean age, 72 years, 2 males and 4 females) and in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (mean age, 38 years, 25 males and 155 females) were similar to that in healthy male subjects (mean age, 30 years) (see <span class="Bold"><a href="#PreGeriatric">PRECAUTIONS: Geriatric Use</a></span>)<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.4"></a><p></p>
<h3>Race</h3>
<p class="First">The systemic clearance and C<span class="Sub">max</span> of sumatriptan were similar in black (N = 34) and Caucasian (N = 38) healthy male subjects. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="CPDIMOI"></a><a name="section-3.6.1"></a><p></p>
<h3>Monoamine Oxidase Inhibitors</h3>
<p class="First"><span class="Italics">In vitro</span> studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme. In a study of 14 healthy females, pretreatment with MAO-A inhibitor decreased the clearance of sumatriptan. Under the conditions of this experiment, the result was a 2-fold increase in the area under the sumatriptan plasma concentration x time curve (AUC), corresponding to a 40% increase in elimination half-life. No significant effect was seen with an MAO-B inhibitor. </p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-3.7"></a><p></p>
<h2>Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.7.1"></a><p></p>
<h3>Typical Physiologic Responses</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.7.1.1"></a><p></p>
<h4>Blood Pressure</h4>
<p class="First">(see <span class="Bold"><a href="#WarnIBP">WARNINGS: Increase in Blood Pressure</a>.</span>) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.7.1.2"></a><p></p>
<h4>Peripheral (small) Arteries</h4>
<p class="First">In healthy volunteers (N = 18), a study evaluating the effects of sumatriptan on peripheral (small vessel) arterial reactivity failed to detect a clinically significant increase in peripheral resistance. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.7.1.3"></a><p></p>
<h4>Heart Rate</h4>
<p class="First">Transient increases in blood pressure observed in some patients in clinical studies carried out during sumatriptan's development as a treatment for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> were not accompanied by any clinically significant changes in heart rate. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.7.1.4"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">Respiratory Rate</span></h4>
<p class="First">Experience gained during the clinical development of sumatriptan as a treatment for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> failed to detect an effect of the drug on <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>. </p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">In US controlled clinical trials enrolling more than 1,000 patients during <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks who were experiencing moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and 1 or more of the symptoms enumerated in <span class="Bold"><a href="#table2">Table 2</a>,</span> onset of relief began as early as 10 minutes following a 6-mg sumatriptan succinate injection. Smaller doses of sumatriptan may also prove effective, although the proportion of patients obtaining adequate relief is decreased and the latency to that relief is greater. </p>
<p>In 1 well-controlled study where placebo (n = 62) was compared to 6 different doses of sumatriptan succinate injection (n = 30 each group) in a single-attack, parallel-group design, the dose response relationship was found to be as shown in <span class="Bold"><a href="#table1">Table 1</a>. </span></p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1. Dose Response Relationship for Efficacy</span></caption>
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead><tr class="First Last">
<th align="center">Sumatriptan succinate Dose (mg) </th>
<th align="center">% Patients With Relief<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> at 10 Minutes </th>
<th align="center">% Patients With Relief<a href="#footnote-1" class="Sup">*</a> at 30 Minutes</th>
<th align="center">% Patients With Relief<a href="#footnote-1" class="Sup">*</a> at 1 Hour </th>
<th align="center">% Patients With Relief<a href="#footnote-1" class="Sup">*</a> at 2 Hours </th>
<th align="center">Adverse Events Incidence (%)</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Relief is defined as the reduction of moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to no or mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after dosing without use of rescue medication.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">Placebo</td>
<td align="center">5</td>
<td align="center">15</td>
<td align="center">24</td>
<td align="center">21</td>
<td align="center">55</td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">10</td>
<td align="center">40</td>
<td align="center">43</td>
<td align="center">40</td>
<td align="center">63</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">7</td>
<td align="center">23</td>
<td align="center">57</td>
<td align="center">43</td>
<td align="center">63</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">17</td>
<td align="center">47</td>
<td align="center">57</td>
<td align="center">60</td>
<td align="center">77</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">13</td>
<td align="center">37</td>
<td align="center">50</td>
<td align="center">57</td>
<td align="center">80</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">10</td>
<td align="center">63</td>
<td align="center">73</td>
<td align="center">70</td>
<td align="center">83</td>
</tr>
<tr class="Last">
<td align="center">8</td>
<td align="center">23 </td>
<td align="center">57 </td>
<td align="center">80 </td>
<td align="center">83 </td>
<td align="center">93 </td>
</tr>
</tbody>
</table>
<p>In 2 US well-controlled clinical trials in 1,104 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients with moderate or severe <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, the onset of relief was rapid (less than 10 minutes) with sumatriptan succinate injection 6 mg. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> relief, as evidenced by a reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from severe or moderately severe to mild or no <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, was achieved in 70% of the patients within 1 hour of a single 6-mg subcutaneous dose of sumatriptan succinate injection. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> relief was achieved in approximately 82% of patients within 2 hours, and 65% of all patients were <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> free within 2 hours. </p>
<p><span class="Bold"><a href="#table2">Table 2</a></span> shows the 1- and 2-hour efficacy results for sumatriptan succinate injection 6 mg. </p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2. Efficacy Data From US Phase III Trials</span></caption>
<col align="left" valign="middle" width="28%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>p&lt;0.05 versus placebo.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>A successful outcome in terms of clinical <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> was defined prospectively as ability to work mildly impaired or ability to work and function normally.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>Includes patients that may have received an additional placebo injection 1 hour after the initial injection.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">§</a></dt>
<dd>Includes patients that may have received an additional 6 mg of sumatriptan succinate injection 1 hour after the initial injection.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td align="left"></td>
<td align="center" colspan="2">Study 1 </td>
<td align="center" colspan="2">Study 2 </td>
</tr>
<tr class="Botrule">
<td align="center">1-Hour Data </td>
<td align="center">Placebo<br>(n = 190)</td>
<td align="center">Sumatriptan succinate<br>6 mg (n = 384) </td>
<td align="center">Placebo<br>(n = 180) </td>
<td align="center">Sumatriptan succinate<br>6 mg (n = 350) </td>
</tr>
<tr class="Botrule">
<td align="left">Patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief (grade 0/1) </td>
<td align="center">18 %</td>
<td align="center">70%<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">26% </td>
<td align="center">70%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Patients with no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </td>
<td align="center">5%</td>
<td align="center">48%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">13% </td>
<td align="center">49%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Patients without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </td>
<td align="center">48%</td>
<td align="center">73%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">50% </td>
<td align="center">73%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Patients without <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> </td>
<td align="center">23%</td>
<td align="center">56%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">25% </td>
<td align="center">58%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Patients with little or no clinical <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td>
<td align="center">34%</td>
<td align="center">76%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">34% </td>
<td align="center">76%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center" colspan="2">Study 1 </td>
<td align="center" colspan="2">Study 2</td>
</tr>
<tr class="Botrule">
<td align="center">2-Hour Data </td>
<td align="center">Placebo<a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a>
</td>
<td align="center">Sumatriptan succinate<br> 6 mg<a name="footnote-reference-5" href="#footnote-5" class="Sup">§</a>
</td>
<td align="center">Placebo<a href="#footnote-4" class="Sup">‡</a>
</td>
<td align="center">Sumatriptan succinate<br> 6 mg<a href="#footnote-5" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief (grade 0/1) </td>
<td align="center">31% </td>
<td align="center">81%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">39% </td>
<td align="center">82%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Patients with no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="center">11% </td>
<td align="center">63%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">19% </td>
<td align="center">65%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Patients without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </td>
<td align="center">56% </td>
<td align="center">82%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">63% </td>
<td align="center">81%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">Patients without <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> </td>
<td align="center">31% </td>
<td align="center">72%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">35% </td>
<td align="center">71%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td align="left">Patients with little or no clinical <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span><a href="#footnote-3" class="Sup">†</a>
</td>
<td align="center">42% </td>
<td align="center">85%<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">49% </td>
<td align="center">84%<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
<p>Sumatriptan succinate injection also relieved <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> (sound sensitivity), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Similar efficacy was seen when patients self-administered sumatriptan succinate injection using an autoinjector. </p>
<p>The efficacy of sumatriptan succinate injection is unaffected by whether or not <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> is associated with <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>, duration of attack, gender or age of the patient, or concomitant use of common <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> drugs (e.g., beta-blockers). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">Cluster Headache</span></h2>
<p class="First">The efficacy of sumatriptan succinate injection in the acute treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> was demonstrated in 2 randomized, double-blind, placebo-controlled,2-period crossover trials. Patients age 21 to 65 were enrolled and were instructed to treat a moderate to very severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> within 10 minutes of onset. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> relief was defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In both trials, the proportion of individuals gaining relief at 10 or 15 minutes was significantly greater among patients receiving 6 mg of sumatriptan succinate injection compared to those who received placebo (see <span class="Bold"><a href="#table3">Table 3</a></span>). One study evaluated a 12-mg dose; there was no statistically significant difference in outcome between patients randomized to the 6- and 12-mg doses. </p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3. Efficacy Data From the Pivotal <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">Cluster Headache</span> Studies</span></caption>
<col align="left" valign="middle" width="28%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="2">Study 1 </th>
<th align="center" colspan="2">Study 2 </th>
</tr>
<tr class="Botrule Last">
<th align="left"></th>
<th align="center">Placebo<br>(n = 39)</th>
<th align="center">Sumatriptan succinate<br>6 mg (n = 39) </th>
<th align="center">Placebo<br>(n = 88) </th>
<th align="center">Sumatriptan succinate<br>6 mg (n = 92) </th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">(n = Number of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> treated.)</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>p&lt;0.05.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First"><td align="left" colspan="5">Patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief (no/mild) </td></tr>
<tr>
<td align="left">5 minutes postinjection </td>
<td align="center">8% </td>
<td align="center">21% </td>
<td align="center">7% </td>
<td align="center">23%<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">10 minutes postinjection </td>
<td align="center">10% </td>
<td align="center">49%<a href="#footnote-6" class="Sup">*</a>
</td>
<td align="center">25% </td>
<td align="center">49%<a href="#footnote-6" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td align="left">15 minutes postinjection </td>
<td align="center">26% </td>
<td align="center">74%<a href="#footnote-6" class="Sup">*</a>
</td>
<td align="center">35% </td>
<td align="center">75%<a href="#footnote-6" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
<p>The Kaplan-Meier (product limit) Survivorship Plot (<span class="Bold"><a href="#fig1">Figure 1</a></span>) provides an estimate of the cumulative probability of a patient with a <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> obtaining relief after being treated with either sumatriptan or placebo. </p>
<p><a name="fig1"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24259865-233b-4258-a01b-e895a873f2c4&amp;name=sumatriptan-02.jpg"></p>
<p>*Patients taking rescue medication were censored at 15 minutes. </p>
<p>The plot was constructed with data from patients who either experienced relief or did not require (request) rescue medication within a period of 2 hours following treatment. As a consequence, the data in the plot are derived from only a subset of the 258 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> treated (rescue medication was required in 52 of the 127 placebo-treated <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and 18 of the 131 sumatriptan-treated <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>). </p>
<p>Other data suggest that sumatriptan treatment is not associated with an increase in early recurrence of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and that treatment with sumatriptan has little effect on the incidence of latter-occurring <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (i.e., those occurring after 2, but before 18 or 24 hours). </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Sumatriptan succinate injection is indicated for 1) the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> and 2) the acute treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> episodes. </p>
<p>Sumatriptan succinate injection is not for use in the management of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>). </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">Sumatriptan succinate injection should not be given intravenously because of its potential to cause <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span>.</span></p>
<p><span class="Bold">Sumatriptan succinate injection should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptan succinate injection. Ischemic cardiac syndromes include, but are not limited to, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal variant), all forms of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and silent <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>. Cerebrovascular syndromes include, but are not limited to, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> of any type as well as <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span>. <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> includes, but is not limited to, ischemic bowel disease (see <a href="#WarnOVRE">WARNINGS: Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events</a> and <a href="#WarnRisk">WARNINGS: Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</a>).</span></p>
<p><span class="Bold">Because sumatriptan succinate injection may increase blood pressure, it should not be given to patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</span></p>
<p><span class="Bold">Sumatriptan succinate injection and any ergotamine-containing or ergot-type medication (like dihydroergotamine or methysergide) should not be used within 24 hours of each other, nor should sumatriptan succinate injection and another 5-HT<span class="Sub">1</span> agonist.</span></p>
<p><span class="Bold">Sumatriptan succinate injection should not be administered to patients with hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</span></p>
<p><span class="Bold">Sumatriptan succinate injection is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sumatriptan or any of its components.</span></p>
<p><span class="Bold">Sumatriptan succinate injection is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Sumatriptan succinate injection should only be used where a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> has been established. The prescriber should be aware that <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> patients often possess one or more predictive risk factors for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnRisk"></a><a name="section-7.1"></a><p></p>
<h2>Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</h2>
<p class="First"><span class="Bold">Sumatriptan should not be given to patients with documented ischemic or vasospastic CAD (see <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>). It is strongly recommended that sumatriptan not be given to patients in whom unrecognized CAD is predicted by the presence of risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, smoker, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, strong family history of CAD, female with surgical or physiological <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, or male over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> is modest, at best. If, during the cardiovascular evaluation, the patient's medical history or electrocardiographic investigations reveal findings indicative of or consistent with coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, sumatriptan should not be administered (see <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>).</span></p>
<p><span class="Bold">For patients with risk factors predictive of CAD who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of sumatriptan injection take place in the setting of a physician's office or similar medically staffed and equipped facility. Because <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span> can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an electrocardiogram (ECG) during the interval immediately following sumatriptan succinate injection, in these patients with risk factors.</span></p>
<p><span class="Bold">It is recommended that patients who are intermittent long-term users of sumatriptan and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use sumatriptan. In considering this recommendation for periodic cardiovascular evaluation, it is noted that patients with <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> are predominantly male and over 40 years of age, which are risk factors for CAD.</span></p>
<p>The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to sumatriptan. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Drug-Associated Cardiac Events and Fatalities</h2>
<p class="First">Serious adverse cardiac events, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, life-threatening disturbances of cardiac rhythm, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported within a few hours following the administration of sumatriptan succinate injection or sumatriptan succinate tablets. Considering the extent of use of sumatriptan in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, the incidence of these events is extremely low. </p>
<p>The fact that sumatriptan can cause <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span>, that some of these events have occurred in patients with no prior cardiac disease history and with documented absence of CAD, and the close proximity of the events to sumatriptan use support the conclusion that some of these cases were caused by the drug. In many cases, however, where there has been known underlying CAD, the relationship is uncertain. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<h3>Premarketing Experience With Sumatriptan</h3>
<p class="First">Among the more than 1,900 patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> who participated in premarketing controlled clinical trials of subcutaneous sumatriptan, there were 8 patients who sustained clinical events during or shortly after receiving sumatriptan that may have reflected coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>. Six of these 8 patients had ECG changes consistent with transient <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, but without accompanying clinical symptoms or signs. Of these 8 patients, 4 had either findings suggestive of CAD or risk factors predictive of CAD prior to study enrollment. </p>
<p>Of 6,348 patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> who participated in premarketing controlled and uncontrolled clinical trials of oral sumatriptan, 2 experienced clinical adverse events shortly after receiving oral sumatriptan that may have reflected <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span>. Neither of these adverse events was associated with a serious clinical outcome. </p>
<p>Among approximately 4,000 patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> who participated in premarketing controlled and uncontrolled clinical trials of sumatriptan nasal spray, 1 patient experienced an asymptomatic subendocardial <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> possibly subsequent to a coronary vasospastic event. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<h3>Postmarketing Experience With Sumatriptan</h3>
<p class="First">Serious cardiovascular events, some resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in association with the use of sumatriptan succinate injection or sumatriptan succinate tablets. The uncontrolled nature of postmarketing surveillance, however, makes it impossible to determine definitively the proportion of the reported cases that were actually caused by sumatriptan or to reliably assess causation in individual cases. On clinical grounds, the longer the latency between the administration of sumatriptan succinate and the onset of the clinical event, the less likely the association is to be causative. Accordingly, interest has focused on events beginning within 1 hour of the administration of sumatriptan succinate. </p>
<p>Cardiac events that have been observed to have onset within 1 hour of sumatriptan administration include: coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, transient <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>Some of these events occurred in patients who had no findings of CAD and appear to represent consequences of coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>. However, among domestic reports of serious cardiac events within 1 hour of sumatriptan administration, the majority had risk factors predictive of CAD and the presence of significant underlying CAD was established in most cases (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnDACEF"></a><a name="section-7.3"></a><p></p>
<h2>Drug-Associated Cerebrovascular Events and Fatalities</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and other cerebrovascular events have been reported in patients treated with oral or subcutaneous sumatriptan, and some have resulted in fatalities. The relationship of sumatriptan to these events is uncertain. In a number of cases, it appears possible that the cerebrovascular events were primary, sumatriptan having been administered in the incorrect belief the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> when they were not. As with other <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> therapies, before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. It should also be noted that patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be at increased risk of certain cerebrovascular events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, transient ischemic attack). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnOVRE"></a><a name="section-7.4"></a><p></p>
<h2>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events</h2>
<p class="First">Sumatriptan may cause vasospastic reactions other than coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>. Both peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and colonic <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> have been reported. Very rare reports of transient and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and significant partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> have been reported with the use of sumatriptan. Visual disorders may also be part of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may occur with triptans, including treatment with sumatriptan, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnIBP"></a><a name="section-7.6"></a><p></p>
<h2>Increase in Blood Pressure</h2>
<p class="First">Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, has been reported on rare occasions in patients with and without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Sumatriptan is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>). Sumatriptan should be administered with caution to patients with controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> as transient increases in blood pressure and peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> have been observed in a small proportion of patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnCDU"></a><a name="section-7.7"></a><p></p>
<h2>Concomitant Drug Use</h2>
<p class="First">In patients taking MAO-A inhibitors, sumatriptan plasma levels attained after treatment with recommended doses are nearly double those obtained under other conditions. Accordingly, the coadministration of sumatriptan and an MAO-A inhibitor is not generally recommended. If such therapy is clinically warranted, however, suitable dose adjustment and appropriate observation of the patient is advised (see <span class="Bold"><a href="#CPDIMOI">CLINICAL PHARMACOLOGY: Drug Interactions: Monoamine Oxidase Inhibitors</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2>Use in Women of Childbearing Potential</h2>
<p class="First">(see <span class="Bold"><a href="#PrePreg">PRECAUTIONS: Pregnancy</a></span>) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarnHypersensitivity"></a><a name="section-7.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>/anaphylactoid) reactions have occurred on rare occasions in patients receiving sumatriptan. Such reactions can be life threatening or fatal. In general, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="PreGen"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Chest, jaw, or <span class="product-label-link" type="condition" conceptid="4097447" conceptname="Muscle tension">neck tightness</span> is relatively common after administration of sumatriptan succinate injection. <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span> and jaw or <span class="product-label-link" type="condition" conceptid="4097447" conceptname="Muscle tension">neck tightness</span> have been reported following use of sumatriptan succinate tablets and have also been reported infrequently following the administration of sumatriptan succinate nasal spray. Only rarely have these symptoms been associated with ischemic ECG changes. However, because sumatriptan may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, patients who experience signs or symptoms suggestive of angina following sumatriptan should be evaluated for the presence of CAD or a predisposition to Prinzmetal <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> before receiving additional doses of sumatriptan and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud syndrome, following sumatriptan should be evaluated for <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> or predisposition to <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (see <span class="Bold"><a href="#WarnRisk">WARNINGS: Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</a> and <a href="#WarnOVRE">WARNINGS: Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events</a></span>). </p>
<p>Sumatriptan succinate should also be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs, such as impaired hepatic or renal function. </p>
<p>There have been rare reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> following administration of sumatriptan. Sumatriptan should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or conditions associated with a lowered <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. </p>
<p>Care should be taken to exclude other potentially serious neurologic conditions before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> in patients not previously diagnosed with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> or who experience a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> that is atypical for them. There have been rare reports where patients received sumatriptan for severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> that were subsequently shown to have been secondary to an evolving neurologic lesion (see <span class="Bold"><a href="#WarnDACEF">WARNINGS: Drug-Associated Cerebrovascular Events and Fatalities</a></span>). For a given attack, if a patient does not respond to the first dose of sumatriptan, the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> should be reconsidered before administration of a second dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Binding to Melanin-Containing Tissues</h2>
<p class="First">Because sumatriptan binds to melanin, it could accumulate in melanin-rich tissues (such as the eye) over time. This raises the possibility that sumatriptan could cause toxicity in these tissues after extended use. However, no effects on the retina related to treatment with sumatriptan were noted in any of the toxicity studies. Although no systematic monitoring of ophthalmologic function was undertaken in clinical trials, and no specific recommendations for ophthalmologic monitoring are offered, prescribers should be aware of the possibility of long-term ophthalmologic effects (see <span class="Bold"><a href="#CPMB">CLINICAL PHARMACOLOGY: Melanin Binding</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Corneal Opacities</h2>
<p class="First">Sumatriptan causes corneal opacities and defects in the corneal epithelium in dogs; this raises the possibility that these changes may occur in humans. While patients were not systematically evaluated for these changes in clinical trials, and no specific recommendations for monitoring are being offered, prescribers should be aware of the possibility of these changes (see <span class="Bold"><a href="#CPCO">CLINICAL PHARMACOLOGY: Corneal Opacities</a></span>). </p>
<p><span class="Bold">Patients who are advised to self-administer sumatriptan succinate injection in medically unsupervised situations should receive instruction on the proper use of the product from the physician or other suitably qualified health care professional prior to doing so for the first time.</span></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Since the injection is intended to be given subcutaneously, intramuscular or intravascular delivery should be avoided. Patients should be directed to use injection sites with an adequate skin and subcutaneous thickness to accommodate the length of the needle. See the <span class="Bold"><a href="#PPI">Information for the Patient</a></span> provided in the separate leaflet.</p>
<p>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of sumatriptan or other triptans, especially during combined use with SSRIs or SNRIs.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8.5"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">No specific laboratory tests are recommended for monitoring patients prior to and/or after treatment with sumatriptan. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.6"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.1"></a><p></p>
<h3>Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h3>
<p class="First">Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during combined use of SSRIs or SNRIs and triptans (see <a href="#Warnings">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Medications</h3>
<p class="First">There is no evidence that concomitant use of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> medications has any effect on the efficacy of sumatriptan. In 2 Phase III trials in the US, a retrospective analysis of 282 patients who had been using <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> drugs (verapamil n = 63, amitriptyline n = 57, propranolol n = 94, for 45 other drugs n = 123) were compared to those who had not used prophylaxis (N = 452). There were no differences in relief rates at 60 minutes postdose for sumatriptan succinate injection, whether or not <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> medications were used. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.3"></a><p></p>
<h3>Ergot-Containing Drugs</h3>
<p class="First">Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.4"></a><p></p>
<h3>Monoamine Oxidase-A Inhibitors</h3>
<p class="First">MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, the use of sumatriptan in patients receiving MAO-A inhibitors is not ordinarily recommended. If the clinical situation warrants the combined use of sumatriptan and an MAOI, the dose of sumatriptan employed should be reduced (see <span class="Bold"><a href="#CPDIMOI">CLINICAL PHARMACOLOGY: Drug Interactions: Monoamine Oxidase Inhibitors</a></span><span class="Italics"> and </span><span class="Bold"><a href="#WarnCDU">WARNINGS: Concomitant Drug Use</a></span><span class="Italics">)</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-8.7"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Sumatriptan succinate is not known to interfere with commonly employed clinical laboratory tests. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.8"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In carcinogenicity studies, rats and mice were given sumatriptan by oral gavage (rats, 104 weeks) or drinking water (mice, 78 weeks). Average exposures achieved in mice receiving the highest dose were approximately 110 times the exposure attained in humans after the maximum recommended single dose of 6 mg. The highest dose to rats was approximately 260 times the maximum single dose of 6 mg on a mg/m<span class="Sup">2</span> basis. There was no evidence of an increase in tumors in either species related to sumatriptan administration. </p>
<p>Sumatriptan was not mutagenic in the presence or absence of metabolic activation when tested in 2 gene mutation assays (the Ames test and the <span class="Italics">in vitro</span> mammalian Chinese hamster V79/HGPRT assay). In 2 cytogenetics assays (the <span class="Italics">in vitro</span> human lymphocyte assay and the <span class="Italics">in vivo</span> rat micronucleus assay) sumatriptan was not associated with clastogenic activity. </p>
<p>A fertility study (Segment I) by the subcutaneous route, during which male and female rats were dosed daily with sumatriptan prior to and throughout the mating period, has shown no evidence of impaired fertility at doses equivalent to approximately 100 times the maximum recommended single human dose of 6 mg on a mg/m<span class="Sup">2</span> basis. However, following oral administration, a treatment-related decrease in fertility, secondary to a decrease in mating, was seen for rats treated with 50 and 500 mg/kg/day. The no-effect dose for this finding was approximately 8 times the maximum recommended single human dose of 6 mg on a mg/m<span class="Sup">2</span> basis. It is not clear whether the problem is associated with the treatment of males or females or both. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="PrePreg"></a><a name="section-8.9"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Sumatriptan has been shown to be embryolethal in rabbits when given daily at a dose approximately equivalent to the maximum recommended single human subcutaneous dose of 6 mg on a mg/m<span class="Sup">2</span> basis. There is no evidence that establishes that sumatriptan is a human teratogen; however, there are no adequate and well-controlled studies in pregnant women. Sumatriptan succinate injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>In assessing this information, the following additional findings should be considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.2"></a><p></p>
<h3>Embryolethality</h3>
<p class="First">When given intravenously to pregnant rabbits daily throughout the period of organogenesis, sumatriptan caused embryolethality at doses at or close to those producing maternal toxicity. The mechanism of the embryolethality is not known. These doses were approximately equivalent to the maximum single human dose of 6 mg on a mg/m<span class="Sup">2 </span>basis. </p>
<p>The intravenous administration of sumatriptan to pregnant rats throughout organogenesis at doses that are approximately 20 times a human dose of 6 mg on a mg/m<span class="Sup">2 </span>basis, did not cause embryolethality. Additionally, in a study of pregnant rats given subcutaneous sumatriptan daily prior to and throughout pregnancy, there was no evidence of increased embryo/fetal lethality. </p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.9.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span></h3>
<p class="First">Term fetuses from Dutch Stride rabbits treated during organogenesis with oral sumatriptan exhibited an increased incidence of cervicothoracic vascular and skeletal abnormalities. The functional significance of these abnormalities is not known. The highest no-effect dose for these effects was 15 mg/kg/day, approximately 50 times the maximum single dose of 6 mg on a mg/m<span class="Sup">2</span> basis. </p>
<p>In a study in rats dosed daily with subcutaneous sumatriptan prior to and throughout pregnancy, there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.10"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Sumatriptan is excreted in human breast milk following subcutaneous administration. Infant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hours after treatment with sumatriptan succinate injection.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.11"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of sumatriptan succinate injection in pediatric patients under 18 years of age have not been established; therefore, sumatriptan succinate injection is not recommended for use in patients under 18 years of age. </p>
<p>Two controlled clinical trials evaluating sumatriptan nasal spray (5 to 20 mg) in pediatric patients aged 12 to 17 years enrolled a total of 1,248 adolescent migraineurs who treated a single attack. The studies did not establish the efficacy of sumatriptan nasal spray compared to placebo in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in adolescents. Adverse events observed in these clinical trials were similar in nature to those reported in clinical trials in adults. </p>
<p>Five controlled clinical trials (2 single attack studies, 3 multiple attack studies) evaluating oral sumatriptan (25 to 100 mg) in pediatric patients aged 12 to 17 years enrolled a total of 701 adolescent migraineurs. These studies did not establish the efficacy of oral sumatriptan compared to placebo in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in adolescents. Adverse events observed in these clinical trials were similar in nature to those reported in clinical trials in adults. The frequency of all adverse events in these patients appeared to be both dose- and age-dependent, with younger patients reporting events more commonly than older adolescents. </p>
<p>Postmarketing experience documents that serious adverse events have occurred in the pediatric population after use of subcutaneous, oral, and/or intranasal sumatriptan. These reports include events similar in nature to those reported rarely in adults, including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, visual loss, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. A <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been reported in a 14-year-old male following the use of oral sumatriptan; clinical signs occurred within 1 day of drug administration. Since clinical data to determine the frequency of serious adverse events in pediatric patients who might receive injectable, oral, or intranasal sumatriptan are not presently available, the use of sumatriptan in patients aged younger than 18 years is not recommended. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="PreGeriatric"></a><a name="section-8.12"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">The use of sumatriptan in elderly patients is not recommended because elderly patients are more likely to have decreased hepatic function, they are at higher risk for CAD, and blood pressure increases may be more pronounced in the elderly (see <span class="Bold"><a href="#WarnRisk">WARNINGS: Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</a></span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan succinate injection or tablets. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, transient <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> (</span>see<span class="Bold"><a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a>, <a href="#WarnRisk">WARNINGS: Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</a>, </span>and<span class="Bold"><a href="#PreGen"> PRECAUTIONS: General</a></span>). </p>
<p>Significant <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span>, including hypertensive crises, have been reported on rare occasions in patients with or without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (see <span class="Bold"><a href="#WarnIBP">WARNINGS: Increase in Blood Pressure</a></span>). </p>
<p>Among patients in clinical trials of subcutaneous sumatriptan succinate injection (N = 6,218), up to 3.5% of patients withdrew for reasons related to adverse events. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Incidence in Controlled Clinical Trials of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine Headache</span></h2>
<p class="First"><span class="Bold"><a href="#table4">Table 4</a></span> lists adverse events that occurred in 2 large US, Phase III, placebo-controlled clinical trials in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients following either a single 6-mg dose of sumatriptan succinate injection or placebo. Only events that occurred at a frequency of 2% or more in groups treated with sumatriptan succinate injection 6-mg and occurred at a frequency greater than the placebo group are included in <span class="Bold"><a href="#table4">Table 4</a>.</span></p>
<a name="table4"></a><table width="100%">
<caption><span>Table 4. Treatment-Emergent Adverse Experience Incidence in 2 Large Placebo-Controlled <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Clinical Trials: Events Reported by at Least 2% of Patients Treated with Sumatriptan Succinate Injection 6 mg<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="2">Percent of Patients Reporting </th>
</tr>
<tr class="Last">
<th align="center">Adverse Event Type </th>
<th align="center">Sumatriptan succinate injection<br>6 mg Subcutaneous n = 547 </th>
<th align="center">Placebo<br>n = 370 </th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>The sum of the percentages cited is greater than 100% because patients may experience more than 1 type of adverse event. Only events that occurred at a frequency of 2% or more in groups treated with sumatriptan succinate injection and occurred at a frequency greater than the placebo groups are included.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Atypical sensations</td>
<td align="center">42 </td>
<td align="center">9 </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Tingling</span> </td>
<td align="center">14 </td>
<td align="center">3 </td>
</tr>
<tr>
<td align="left">  Warm/hot sensation </td>
<td align="center">11</td>
<td align="center">4 </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">Burning sensation</span> </td>
<td align="center">7 </td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  Feeling of heaviness </td>
<td align="center">7 </td>
<td align="center">1 </td>
</tr>
<tr>
<td align="left">  Pressure sensation </td>
<td align="center">7 </td>
<td align="center">2 </td>
</tr>
<tr>
<td align="left">  Feeling of tightness </td>
<td align="center">5</td>
<td align="center">&lt;1 </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> </td>
<td align="center">5</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">Feeling strange</span> </td>
<td align="center">2 </td>
<td align="center">&lt;1 </td>
</tr>
<tr class="Botrule">
<td align="left">  Tight feeling in head </td>
<td align="center">2 </td>
<td align="center">&lt;1 </td>
</tr>
<tr>
<td align="left">Cardiovascular </td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> </td>
<td align="center">7 </td>
<td align="center">2 </td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span> </td>
<td align="center">5 </td>
<td align="center">1 </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Tightness in chest</span> </td>
<td align="center">3 </td>
<td align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td align="left">  Pressure in chest </td>
<td align="center">2 </td>
<td align="center">&lt;1 </td>
</tr>
<tr>
<td align="left">Ear, nose, and throat </td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Throat <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> </td>
<td align="center">3</td>
<td align="center">&lt;1 </td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span>: nasal cavity/sinuses </td>
<td align="center">2 </td>
<td align="center">&lt;1 </td>
</tr>
<tr class="Botrule">
<td align="left"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> </td>
<td align="center">59 </td>
<td align="center">24 </td>
</tr>
<tr>
<td align="left">Miscellaneous </td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td align="left">  Jaw <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> </td>
<td align="center">2 </td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">Musculoskeletal </td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> </td>
<td align="center">5 </td>
<td align="center">&lt;1 </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span>/<span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> </td>
<td align="center">5 </td>
<td align="center">&lt;1 </td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> </td>
<td align="center">2 </td>
<td align="center">&lt;1 </td>
</tr>
<tr>
<td align="left">Neurological </td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> </td>
<td align="center">12 </td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>/sedation </td>
<td align="center">3 </td>
<td align="center">2 </td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td align="center">2 </td>
<td align="center">&lt;1 </td>
</tr>
<tr>
<td align="left">Skin </td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> </td>
<td align="center">2 </td>
<td align="center">1 </td>
</tr>
</tbody>
</table>
<p>The incidence of adverse events in controlled clinical trials was not affected by gender or age of the patients. There were insufficient data to assess the impact of race on the incidence of adverse events. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Incidence in Controlled Trials of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">Cluster Headache</span></h2>
<p class="First">In the controlled clinical trials assessing sumatriptan's efficacy as a treatment for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>, no new significant adverse events associated with the use of sumatriptan were detected that had not already been identified in association with the drug's use in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. </p>
<p>Overall, the frequency of adverse events reported in the studies of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> were generally lower. Exceptions include reports of <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (5% sumatriptan succinate, 0% placebo), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4% sumatriptan succinate, 0% placebo), and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> (1% sumatriptan succinate, 0% placebo). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Other Events Observed in Association With the Administration of Sumatriptan Succinate Injection</h2>
<p class="First">In the paragraphs that follow, the frequencies of less commonly reported adverse clinical events are presented. Because the reports include events observed in open and uncontrolled studies, the role of sumatriptan succinate injection in their causation cannot be reliably determined. Furthermore, variability associated with adverse event reporting, the terminology used to describe adverse events, etc., limit the value of the quantitative frequency estimates provided. </p>
<p>Event frequencies are calculated as the number of patients reporting an event divided by the total number of patients (N = 6,218) exposed to subcutaneous sumatriptan succinate injection. All reported events are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in at least 1/100 patients, infrequent adverse events are those occurring in 1/100 to 1/1,000 patients, and rare adverse events are those occurring in fewer than 1/1,000 patients. </p>
<p><span class="Bold Italics">Cardiovascular:</span> Infrequent were <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, pulsating sensations, various transient ECG changes (nonspecific ST or T wave changes, prolongation of PR or QTc intervals, <span class="product-label-link" type="condition" conceptid="4217221" conceptname="Nodal rhythm disorder">sinus arrhythmia</span>, nonsustained ventricular <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span>, isolated junctional ectopic beats, atrial ectopic beats, delayed activation of the right ventricle), and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. Rare were <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, abnormal pulse, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, and Raynaud syndrome. </p>
<p><span class="Bold Italics">Endocrine and Metabolic:</span> Infrequent was <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>. Rare were <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. </p>
<p><span class="Bold Italics">Eye:</span> Frequent was vision alterations. Infrequent was irritation of the eye. </p>
<p><span class="Bold Italics">Gastrointestinal:</span> Frequent were <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> and <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Rare were <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="4309379" conceptname="Retching">retching</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>/<span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, and <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>. </p>
<p><span class="Bold Italics">Musculoskeletal:</span> Frequent were <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>. Infrequent were various joint disturbances (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">ache</span>). Rare were <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle stiffness</span>, need to flex calf muscles, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, muscle <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the extremities. </p>
<p><span class="Bold Italics">Neurological:</span> Frequent was <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, relaxation, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, sensation of lightness, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, disturbances of taste, prickling sensations, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> sensations, <span class="product-label-link" type="condition" conceptid="4317968" conceptname="Pain in face">facial pain</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>. Rare were transient <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">hemiplegia</span>, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>, <span class="product-label-link" type="condition" conceptid="4185725" conceptname="Globus hystericus">globus hystericus</span>, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, myoclonia, <span class="product-label-link" type="condition" conceptid="381548" conceptname="Monoplegia">monoplegia</span>/<span class="product-label-link" type="condition" conceptid="4277456" conceptname="Diplegia">diplegia</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbance</span>, difficulties in concentration, disturbances of smell, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, simultaneous hot and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensations, tickling sensations, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, reduced appetite, <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span>, and <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>. </p>
<p><span class="Bold Italics">Respiratory:</span> Infrequent was <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. Rare were <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, diseases of the lower respiratory tract, and <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccoughs</span>. </p>
<p><span class="Bold Italics">Skin:</span> Infrequent were <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span>. Rare was <span class="product-label-link" type="condition" conceptid="4115411" conceptname="Pain of skin">skin tenderness</span>. </p>
<p><span class="Bold Italics">Urogenital:</span> Rare were <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, frequency, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, and <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span>. </p>
<p><span class="Bold Italics">Miscellaneous: </span>Infrequent were miscellaneous laboratory abnormalities, including minor disturbances in liver function tests, "serotonin agonist effect," and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to various agents. Rare was <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>Other Events Observed in the Clinical Development of Sumatriptan Succinate Injection</h2>
<p class="First">The following adverse events occurred in clinical trials with sumatriptan succinate tablets and sumatriptan succinate nasal spray. Because the reports include events observed in open and uncontrolled studies, the role of sumatriptan succinate in their causation cannot be reliably determined. All reported events are included except those already listed, those too general to be informative, and those not reasonably associated with the use of the drug. </p>
<p><span class="Bold Italics">Breasts:</span> <span class="product-label-link" type="condition" conceptid="4114004" conceptname="Swelling of breast">Breast swelling</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>, disorder of breasts, lumps, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span> of breasts, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, primary malignant breast neoplasm, and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>. </p>
<p><span class="Bold Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="198177" conceptname="Abdominal aortic aneurysm">Abdominal aortic aneurysm</span>, angina, <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, cerebrovascular lesion, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, peripheral <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, and transient <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>. </p>
<p><span class="Bold Italics">Ear, Nose, and Throat:</span> <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic rhinitis</span>; disorder of nasal cavity/sinuses; ear, nose, and throat <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infection</span>; external <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>; feeling of fullness in the ear(s); hearing disturbances; <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>; Meniere disease; nasal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">otalgia</span>; sensitivity to noise; <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>; <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; and upper respiratory <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. </p>
<p><span class="Bold Italics">Endocrine and Metabolic:</span> Elevated thyrotropin stimulating hormone (TSH) levels; endocrine <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>, lumps, and <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span>; fluid disturbances; <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>; <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>; <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>; and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. </p>
<p><span class="Bold Italics">Eye:</span> <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">Accommodation disorders</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and low vision, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, disorders of sclera, external ocular <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">muscle disorders</span>, eye <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye itching</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. </p>
<p><span class="Bold Italics">Gastrointestinal:</span> Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, dyspeptic symptoms, feelings of gastrointestinal pressure, gastric symptoms, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>, hyposalivation, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, oral <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and irritation, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="28461" conceptname="Hypertrophy of salivary gland">salivary gland swelling</span>, and <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">swallowing disorders</span>. </p>
<p><span class="Bold Italics">Hematological Disorders:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>.</p>
<p><span class="Bold Italics">Mouth and Teeth:</span> Disorder of mouth and tongue (e.g., burning of tongue, <span class="product-label-link" type="condition" conceptid="4009388" conceptname="Perioral numbness">numbness of tongue</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>). </p>
<p><span class="Bold Italics">Musculoskeletal:</span> Acquired musculoskeletal <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and articular rheumatitis, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="75344" conceptname="Intervertebral disc disorder">intervertebral disc disorder</span>, <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle atrophy</span>, <span class="product-label-link" type="condition" conceptid="4097447" conceptname="Muscle tension">muscle tightness</span> and <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, musculoskeletal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>. </p>
<p><span class="Bold Italics">Neurological:</span> <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">Apathy</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, bad/unusual taste, bradylogia, <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorders</span>, detachment, disturbance of emotions, drug abuse, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial paralysis</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, heat sensitivity, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, increased alertness, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory disturbance</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4203631" conceptname="Motor dysfunction">motor dysfunction</span>, neoplasm of pituitary, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, neurotic disorders, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality change</span>, <span class="product-label-link" type="condition" conceptid="440985" conceptname="Phobia">phobia</span>, <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>, psychomotor disorders, <span class="product-label-link" type="condition" conceptid="4216397" conceptname="Nerve root disorder">radiculopathy</span>, raised intracranial pressure, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, stress, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>. </p>
<p><span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, breathing disorders, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>. </p>
<p><span class="Bold Italics">Skin:</span> Dry/scaly skin, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, herpes, <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">skin nodules</span>, tightness of skin, and <span class="product-label-link" type="condition" conceptid="4013892" conceptname="Crow's feet">wrinkling</span> of skin. </p>
<p><span class="Bold Italics">Urogenital:</span> Abnormal menstrual cycle, abortion, <span class="product-label-link" type="condition" conceptid="4128384" conceptname="Non-infective cystitis">bladder inflammation</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, increased urination, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of fallopian tubes, <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span>, menstruation symptoms, micturition disorders, <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span>, and <span class="product-label-link" type="condition" conceptid="4056621" conceptname="Recurrent urinary tract infection">urinary infections</span>. </p>
<p><span class="Bold Italics">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusions</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">difficulty in walking</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, speech disturbance, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of extremities, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, and <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">voice disturbances</span>. </p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and Other Pressure Sensations:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> and/or heaviness, neck/throat/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>/tightness/pressure, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (location specified). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5"></a><p></p>
<h2>Postmarketing Experience (Reports for Subcutaneous or Oral Sumatriptan)</h2>
<p class="First">The following section enumerates potentially important adverse events that have occurred in clinical practice and that have been reported spontaneously to various surveillance systems. The events enumerated represent reports arising from both domestic and nondomestic use of oral or subcutaneous dosage forms of sumatriptan. The events enumerated include all except those already listed in the <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span> section above or those too general to be informative. Because the reports cite events reported spontaneously from worldwide postmarketing experience, frequency of events and the role of sumatriptan succinate injection in their causation cannot be reliably determined. It is assumed, however, that systemic reactions following sumatriptan use are likely to be similar regardless of route of administration. </p>
<p><span class="Bold Italics">Blood:</span> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. </p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, colonic <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span>), Prinzmetal <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>. </p>
<p><span class="Bold Italics">Ear, Nose, and Throat:</span> <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Deafness</span>. </p>
<p><span class="Bold Italics">Eye:</span> <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">Ischemic optic neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4334245" conceptname="Retinal artery occlusion">retinal artery occlusion</span>, <span class="product-label-link" type="condition" conceptid="4187790" conceptname="Thrombosis of retinal vein">retinal vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>. </p>
<p><span class="Bold Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> with <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">xerostomia</span>. </p>
<p><span class="Bold Italics">Hepatic:</span> Elevated liver function tests. </p>
<p><span class="Bold Italics">Neurological:</span> Central nervous system <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">dysphasia</span>, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>. </p>
<p><span class="Bold Italics">Non-Site Specific:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="4290976" conceptname="Temporal arteritis">temporal arteritis</span>. </p>
<p><span class="Bold Italics">Psychiatry:</span> <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic disorder</span>. </p>
<p><span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> in patients with and without a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. </p>
<p><span class="Bold Italics">Skin:</span> Exacerbation of sunburn, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">allergic vasculitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; in addition, severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported [see <span class="Bold"><a href="#WarnHypersensitivity">WARNINGS: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></span>]), <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>. Following subcutaneous administration of sumatriptan, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, subcutaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and, on rare occasions, <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> (<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in the skin) or <span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">lipohypertrophy</span> (enlargement or thickening of tissue) have been reported. </p>
<p><span class="Bold Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-10"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">The abuse potential of sumatriptan succinate injection cannot be fully delineated in advance of extensive marketing experience. One clinical study enrolling 12 patients with a history of <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> failed to induce subjective behavior and/or physiologic response ordinarily associated with drugs that have an established potential for abuse. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Patients (N = 269) have received single injections of 8 to 12 mg without significant adverse effects. Volunteers (N = 47) have received single subcutaneous doses of up to 16 mg without serious adverse events.</p>
<p>No gross <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in clinical practice have been reported. <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">Coronary vasospasm</span> was observed after intravenous administration of sumatriptan succinate injection (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>). <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> would be expected from animal data (dogs at 0.1 g/kg, rats at 2 g/kg) to possibly cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, inactivity, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the extremities, reduced <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (<span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, and <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scab</span> formation), and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. The half-life of elimination of sumatriptan is about 2 hours (see <span class="Bold"><a href="#CPPharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</a></span>), and therefore monitoring of patients after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with sumatriptan succinate injection should continue while symptoms or signs persist, and for at least 10 hours. </p>
<p>It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The maximum single recommended adult dose of sumatriptan succinate injection is 6 mg injected subcutaneously. If side effects are dose limiting, then lower doses may be used (see <span class="Bold"><a href="#table1">Table 1</a></span>).</p>
<p>The maximum recommended dose that may be given in 24 hours is two 6-mg injections separated by at least 1 hour. Controlled clinical trials have failed to show that clear benefit is associated with the administration of a second 6-mg dose in patients who have failed to respond to a first injection. </p>
<p>In patients receiving MAO inhibitors, decreased doses of sumatriptan should be considered (see <span class="Bold"><a href="#WarnCDU">WARNINGS: Concomitant Drug Use</a> and <a href="#CPDIMOI">CLINICAL PHARMACOLOGY: Drug Interactions: Monoamine Oxidase Inhibitors</a></span>). </p>
<p>Since the injection is intended to be given subcutaneously, intramuscular or intravascular delivery should be avoided. Patients should be directed to use injection sites with an adequate skin and subcutaneous thickness to accommodate the length of the needle. </p>
<p>In patients receiving doses other than 4 or 6 mg, only the 6-mg single-dose vial dosage form should be used.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sumatriptan succinate injection 6 mg/0.5 mL containing sumatriptan 6-mg (base) as the succinate salt is supplied as a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, sterile, nonpyrogenic solution as follows: </p>
<table width="90%">
<col align="left" valign="middle" width="24%">
<col align="left" valign="middle" width="43%">
<col align="left" valign="middle" width="33%">
<thead><tr class="First Last Toprule">
<th align="left">NDC Number</th>
<th align="left">Sumatriptan Succinate Injection</th>
<th align="left">Packaged</th>
</tr></thead>
<tbody><tr class="Botrule First Last Toprule">
<td align="left"><span class="Bold">0703-7351-02</span></td>
<td align="left"><span class="Bold">6-mg Single-dose vials</span></td>
<td align="left"><span class="Bold">in cartons of 5 vials.</span></td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]</span>.<span class="Bold"> May be refrigerated. Protect from light.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Issued: December, 2008</p>
<p>Manufactured by:<br>Teva Parenteral Medicines, Inc.<br>Irvine, CA 92618 </p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="PPI"></a><a name="section-15"></a><p></p>
<h1>Information for the Patient</h1>
<p class="First"><span class="Bold">Sumatriptan Succinate Injection</span></p>
<p>Read this leaflet carefully before you start to take sumatriptan succinate injection. Keep the leaflet for reference because it gives you a summary of important information about sumatriptan succinate injection. </p>
<p>Read the leaflet that comes with each refill of your prescription because there may be new information.</p>
<p>This leaflet does not have all the information about sumatriptan succinate injection. Ask your healthcare provider for more information or advice.</p>
<p><span class="Bold">What is sumatriptan succinate injection?</span></p>
<p>Sumatriptan succinate injection is a 5-HT<span class="Sub">1</span> agonist. It is also called a "triptan." You should use it only if you have a prescription. </p>
<p>Sumatriptan succinate injection is used to relieve your <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>. Sumatriptan succinate injection is not used to prevent attacks or reduce the number of attacks you have. Use sumatriptan succinate injection only to treat an actual <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> attack.</p>
<p>The decision to use sumatriptan succinate injection is one that you and your healthcare provider should make together, taking into account your personal needs and health. </p>
<p><span class="Bold">Talk to your healthcare provider before taking sumatriptan succinate injection</span></p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">Risk factors for heart disease: </span><br>Tell your healthcare provider if you have risk factors for heart disease such as:<ul class="Disc">
<li>high blood pressure,</li>
<li>high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>,</li>
<li>smoking,</li>
<li>strong family history of heart disease,</li>
<li>you are postmenopausal, or</li>
<li>you are a male over 40 years of age.</li>
</ul>							If you do have risk factors for heart disease, your healthcare provider should check you for heart disease to see if sumatriptan succinate is right for you.<br>Although most of the people who have taken sumatriptan succinate have not had any serious side effects, some have had serious heart problems. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> have been reported, but these were rare considering the extensive worldwide use of sumatriptan succinate. Usually, serious problems happened in people with known heart diseases. It was not clear whether sumatriptan succinate had anything to do with these <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. 							 </dd>
</dl>
<p><span class="Bold">Important questions to consider before taking sumatriptan succinate injection</span></p>
<p>If the answer to any of the following questions is <span class="Bold">YES</span> or if you do not know the answer, then please talk with your healthcare provider before you use sumatriptan succinate injection </p>
<ul>
<li>Are you pregnant? Do you think you might be pregnant? Are you trying to become pregnant? Are you using inadequate contraception? Are you breastfeeding?</li>
<li>Do you have any <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, heart disease, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or irregular heartbeats? Have you had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>?</li>
<li>Do you have risk factors for heart disease (such as high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, smoking, strong family history of heart disease, or you are postmenopausal or a male over 40)?</li>
<li>Have you had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> (TIAs), or Raynaud syndrome?</li>
<li>Do you have high blood pressure?</li>
<li>Have you ever had to stop taking this or any other medicine because of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or other problems?</li>
<li>Are you taking any other <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> medicines, including other 5-HT<span class="Sub">1</span> agonists (triptans) or any other medicines containing ergotamine, dihydroergotamine, or methysergide?</li>
<li>Are you taking any medicine for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other disorders such as monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), or serotonin norepinephrine reuptake inhibitors (SNRIs)? Common SSRIs are citalopram HBr (CELEXA<span class="Sup">®</span>), escitalopram oxalate (LEXAPRO<span class="Sup">®</span>), paroxetine (PAXIL<span class="Sup">®</span>), fluoxetine (PROZAC<span class="Sup">®</span>/SARAFEM<span class="Sup">®</span>), olanzapine/fluoxetine (SYMBYAX<span class="Sup">®</span>), sertraline (ZOLOFT<span class="Sup">®</span>), and fluvoxamine. Common SNRIs are duloxetine (CYMBALTA<span class="Sup">®</span>) and venlafaxine (EFFEXOR<span class="Sup">®</span>).<a name="footnote-reference-8" href="#footnote-8" class="Sup">1</a>
</li>
<li>Have you had, or do you have, any disease of the liver or kidney?</li>
<li>Have you had, or do you have, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>?</li>
<li>Is this <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> different from your usual <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks?</li>
</ul>
<p>Remember, if you answered <span class="Bold">YES</span> to any of the above questions, then talk with your healthcare provider about it.</p>
<p><span class="Bold">Important points about sumatriptan succinate injection</span></p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">The use of sumatriptan succinate injection during pregnancy:</span><br>Do not use sumatriptan succinate injection if you are pregnant, think you might be pregnant, are trying to become pregnant, or are not using adequate contraception unless you have talked with your healthcare provider about this.<br> </dd>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">How to use sumatriptan succinate injection:</span><br>For adults, the usual dose is a single injection given just below the skin. You should give an injection as soon as the symptoms of your <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> start, but it may be given at any time during an attack.<br> <br>You may give a second injection if your <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> symptoms come back. If your symptoms do not get better after the first injection, do not give a second injection for the same attack without first talking with your healthcare provider. Do not give more than two 6-mg doses in any 24-hour period. Allow at least 1 hour between each dose.<br> </dd>
<dt class="Bold">3.</dt>
<dd>
<span class="Bold">What to do if you take an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>:</span><br>If you have taken more medicine than has been prescribed for you, contact either your healthcare provider, hospital emergency department, or nearest poison control center immediately.<br> </dd>
<dt class="Bold">4.</dt>
<dd>
<span class="Bold">How to store your medicine:</span><br>Keep your medicine in a safe place where children cannot reach it. It may be harmful to children.<br> <br>Store your medicine away from heat and light. Keep your medicine in the packaging provided. Do not store at temperatures above 77°F (25°C).<br> <br>The expiration date of your medicine is printed on the back of the carton. If your medicine has expired, throw it away as instructed.<br> <br>If your healthcare provider decides to stop your treatment, do not keep any leftover medicine unless your healthcare provider tells you to. Throw away your medicine as instructed.</dd>
</dl>
<p><span class="Bold">Some possible side effects of sumatriptan succinate injection</span></p>
<dl>
<dt>1.</dt>
<dd>Some patients feel <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or tightness in the chest or throat when using sumatriptan succinate injection. If this happens to you, then discuss it with your healthcare provider before using any more sumatriptan succinate injection. If the <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> is severe or does not go away, call your healthcare provider right away.</dd>
<dt>2.</dt>
<dd>Call your healthcare provider right away if you have sudden and/or severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> following sumatriptan succinate injection.</dd>
<dt>3.</dt>
<dd>Some people may have a reaction called <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> when they use certain types of antidepressants, SSRIs or SNRIs, while taking sumatriptan succinate injection. Symptoms may include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, fast heartbeat, feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, difficulty walking, and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Call your doctor immediately if you have any of these symptoms after taking sumatriptan succinate injection.</dd>
<dt>4.</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span>; wheeziness; heart throbbing; <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">swelling of eyelids</span>, face, or lips; or a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, skin lumps, or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> happens rarely. If it happens to you, then tell your healthcare provider right away. Do not take any more sumatriptan succinate injection unless your healthcare provider tells you to.</dd>
<dt>5.</dt>
<dd>Some people may feel <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, heat, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of face lasting a short time), heaviness, or pressure after using sumatriptan succinate injection. A few people may feel drowsy, dizzy, tired, or sick. If you have any of these symptoms, tell your healthcare provider at your next visit.</dd>
<dt>6.</dt>
<dd>You may have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> at the site of injection, but this usually lasts less than an hour.</dd>
<dt>7.</dt>
<dd>If you feel unwell in any other way or have any symptoms that you do not understand, you should contact your healthcare provider right away.</dd>
</dl>
<p>Issued:December, 2008<br>Teva Parenteral Medicines, Inc.<br>Irvine, CA 92618</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">1</a></dt>
<dd>The other brands listed are trademarks of their respective owners and are not trademarks of Teva Parenteral  Medicines. The makers of these brands are not affiliated with and do not endorse Teva Parenteral Medicines or its products.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 6 mg vial label</h1>
<p class="First"><span class="Bold">NDC 0703-7351-02<br>Rx only</span></p>
<p><span class="Bold">Sumatriptan<br>Succinate Injection</span></p>
<p><span class="Bold">6 mg* (Base)/ 0.5 mL</span></p>
<p>For Subcutaneous Injection Only<br>Discard Unused Portion</p>
<p><span class="Bold">5 × 0.5 mL Single-Dose Vials</span></p>
<p><span class="Bold">TEVA</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 6 mg vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24259865-233b-4258-a01b-e895a873f2c4&amp;name=sumatriptan-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUMATRIPTAN SUCCINATE 		
					</strong><br><span class="contentTableReg">sumatriptan succinate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0703-7351</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Sumatriptan Succinate</strong> (Sumatriptan) </td>
<td class="formItem">Sumatriptan Succinate</td>
<td class="formItem">6 mg  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">3.5 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-7351-02</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-7351-01</td>
<td class="formItem">0.5 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077907</td>
<td class="formItem">02/06/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Parenteral Medicines, Inc
							(794362533)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Teva Parenteral Medicines, Inc</td>
<td class="formItem"></td>
<td class="formItem">794362533</td>
<td class="formItem">Manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8bb5c1a2-4e1f-4abe-9019-526481dd1df2</div>
<div>Set id: 24259865-233b-4258-a01b-e895a873f2c4</div>
<div>Version: 2</div>
<div>Effective Time: 20091028</div>
</div>
</div> <div class="DistributorName">Teva Parenteral Medicines, Inc</div></p>
</body></html>
